Minimum age set for UK puberty blocker trial
Researchers agreed to start with 11-year-olds and 12-year-olds after regulators strengthened safeguards and paused recruitment until legal challenges are resolved.
- The Medicines and Healthcare products Regulatory Agency approved a modified protocol for the Pathways trial, establishing minimum entry ages of 11 for birth-registered females and 12 for birth-registered males.
- Regulators paused the study in February, citing safety concerns and lack of age limits, after the MHRA initially recommended a minimum age of 14 due to potential unquantified biological risks.
- King's College London researchers confirmed parental consent remains mandatory, adding that participants must demonstrate "a good understanding of the intervention and its possible benefits and risks."
- Despite the new safeguards, campaigners claim the ethical approval process "contained serious flaws" and seek legal action, though LGBTQ+ charity Stonewall said the group was "pleased" a protocol was agreed.
- Recruitment is scheduled to begin in August, pending the outcome of legal proceedings, as the trial operates under the United Kingdom's 2024 permanent ban on puberty blockers for minors.
11 Articles
11 Articles
UK Approves Trans Puberty Blocker Experiments on Children as Young as 11.
Britain’s Labour Party government has allowed a contentious trial administering puberty blockers to children to restart, despite previous safety concerns and legal challenges. PULSE POINTS WHAT HAPPENED: Britain’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved new protocols for the so-called Pathways trial, allowing children as young as 11 to receive puberty blockers. This decision comes after the trial was previously …
UK Sets 11 Years as Minimum Age for Puberty Blockers in 'Pathways Trial’
The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has determined that it is setting a minimum age requirement of 11 years for subjects to be given puberty blockers in the controversial ‘Pathways’ clinical trial. The trial was suspended in February 2026, following concerns raised by MHRA over a lack of age limits for subjects taking puberty blockers. The agency’s original recommendation was 14 years for the age …
UK Sets 11 Years as Minimum Age for Puberty Blockers in ‘Pathways Trial’
The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has determined that it is setting a minimum age requirement of 11 years for subjects to be given puberty blockers in the controversial ‘Pathways’ clinical trial. The trial was suspended in February 2026, following concerns raised by MHRA over a lack of age...
NHS to hand puberty blockers to 11-year-olds despite ‘biological harm’ warning
The NHS will begin recruiting children as young as 11 for its puberty blocker trial from August despite Britain's medicines regulator previously warning of "potentially significant" long-term biological harms.
Coverage Details
Bias Distribution
- 80% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
